These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24380648)

  • 1. Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Tombal B
    Eur Urol; 2014 Apr; 65(4):e56. PubMed ID: 24380648
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Sciarra A
    Eur Urol; 2014 Apr; 65(4):e57. PubMed ID: 24388442
    [No Abstract]   [Full Text] [Related]  

  • 3. Intermittent androgen deprivation therapy: clarity from confusion.
    Klotz L
    Eur Urol; 2013 Nov; 64(5):731-3. PubMed ID: 23866956
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur Urol 2013;64:517-8.
    Canipari C; Caroti C; Boccardo F
    Eur Urol; 2014 Apr; 65(4):e54-5. PubMed ID: 24341956
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8.
    Cronauer MV; Schrader MG; Schrader AJ
    Eur Urol; 2014 Jan; 65(1):e10-1. PubMed ID: 23993161
    [No Abstract]   [Full Text] [Related]  

  • 7. Intermittent androgen deprivation therapy in prostate cancer: is everything so clear?
    Mottet N
    Eur Urol; 2013 Jan; 63(1):121-2; discussion 123-4. PubMed ID: 22921963
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Per-Anders Abrahamsson. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
    Drewa T
    Eur Urol; 2010 Jul; 58(1):e4; author reply e5-6. PubMed ID: 20363067
    [No Abstract]   [Full Text] [Related]  

  • 9. Castration-resistant prostate cancer: adaptation or clonal selection? Insight from the EORTC 30891 trial.
    Tombal B
    Eur Urol; 2014 Nov; 66(5):839-40. PubMed ID: 24341957
    [No Abstract]   [Full Text] [Related]  

  • 10. Intermittent androgen suppression. Too good to be true?
    Abrahamsson PA
    Scand J Urol Nephrol Suppl; 1999; 203():45-9. PubMed ID: 10636570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
    Printz C
    Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Words of wisdom: Re: Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
    Tombal B
    Eur Urol; 2014 May; 65(5):1013-4. PubMed ID: 24646499
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Penson DF
    J Urol; 2016 Feb; 195(2):353. PubMed ID: 26852977
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
    Lu K
    Eur Urol; 2015 Sep; 68(3):e55-6. PubMed ID: 25865060
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
    Ku JY; Lee JZ; Ha HK
    Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiandrogen withdrawal syndrome].
    Akimoto S
    Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?
    Park JC; Eisenberger MA
    J Clin Oncol; 2016 Jan; 34(3):211-4. PubMed ID: 26628474
    [No Abstract]   [Full Text] [Related]  

  • 19. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
    JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
    Mearini L
    Int Braz J Urol; 2014; 40(2):287-8. PubMed ID: 24856502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.